descriptionPublicationkeyboard_double_arrow_right Article 03 Aug 2022Publisher:Canadian Journal of Health Technologies, CADTHJournal:Canadian Journal of Health Technologies, volume 2 (eissn: 2563-6596,

Authors: null CADTH;

doi: 10.51731/cjht.2022.460 , 10.51731/cjht.2022.407 , 10.51731/cjht.2022.478 , 10.51731/cjht.2023.543

Ruxolitinib (Jakavi)

- Summary
- Metrics

Abstract

CADTH recommends that Jakavi be reimbursed by public drug plans for the treatment of steroid-refractory or steroid-dependent acute graft-versus-host disease (aGvHD) if certain conditions are met. Jakavi should only be covered to treat adults and pediatric patients aged 12 years and older who have steroid-refractory or steroid-dependent aGvHD. Jakavi should only be reimbursed if prescribed by a specialist who has experience in the diagnosis and management of patients with aGvHD, and the cost of Jakavi is reduced.

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average